6533b7d9fe1ef96bd126cc73
RESEARCH PRODUCT
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)
Gianenrico SennaFrancesco MazzaSaniLuigi MacchiaAngelo CorsicoPierluigi PaggiaroFrancesco BlasiLuisa RicciardiCarlo LombardiVittorio VivianoFabio Luigi Massimo RicciardoloEleonora NuceraMaria Pia Foschino BarbaroGabriella GuarnieriGiorgio Walter CanonicaLuca RicheldiErminia RidoloGianna CamiciottoliMarcello MontagniGiuseppe SpadaroFrancesca PuggioniManlio MilaneseMarco CaminatiPierachille SantusMona-rita YacoubCecilia CalabreseMaria D'amatoCristiano CarusoAntonio SpanevelloStefano CentanniNunzio CrimiGiovanni PassalacquaAndrea VianelloLorenzo CosmiMaria Filomena CaiaffaPaolo MontuschiA. FarsiRoberta ParenteLuisa BrussinoCaterina BuccaStefano Del GiaccoGiovanni RollaMaria Teresa CostantinoFrancesco MenzellaMaria Cristina ZappaMaria Elisabetta ConteGiovanna Elisiana CarpagnanoMarco BonaviaGirolamo PelaiaDiego BagnascoGiuseppe GuidaLaura PiniStefano AlibertiSalvatore Lo CiceroEnrico HefflerVincenzo PatellaMatteo BoniniSimona D’aloManuela LatorreNicola ScichiloneElisabetta Faverosubject
ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &Grading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluationdescription
According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-10-01 |